

Study on Best Practices in the Public Procurement of Medicines (PPM)

Public procurement of medicines (PPM) is an important policy that can contribute to more affordable patient access to needed medicines. Acknowledging its optimisation potential and under the mandate of the European Commission, the European Health and Digital Executive Agency (HaDEA) commissioned a **study on best practices in the PPM**. The study is conducted by Gesundheit Österreich Beratungs GmbH (Austrian National Public Health Institute) and Tetra Tech SP. Z.O.O. Findings of the study are expected to become publicly available in Q4/2022.

The **general study objective** is to collect and analyse evidence to **optimise PPM as a tool** that can contribute to accessibility, affordability and availability of medicines, and to encourage greener pharmaceutical design and manufacturing as well as to support crisis preparedness and handling in both outpatient and hospital sectors. Results are aimed to feed the (non-legislative) work of the **Pharmaceutical Strategy for Europe**.

32 countries:
27 EU Member States, EEA/EFTA countries and the UK



Definition of PPM for the purpose of the study in line with EU Procurement Directives: All aspects surrounding the process of purchasing medicines (e.g. for inpatient and outpatient use) by a contracting authority, such as a body of public law (e.g. governments, local health authorities, and social health insurance institutions) or an institution affiliated to the public sector (e.g. not-for-profit institution), from economic operators chosen by the contracting authority. The study acknowledges the importance of supporting policies in the pharmaceutical value chain (such as managed-entry agreements and policies to encourage uptake of generic and biosimilar medicines) and analyses their contribution towards effective PPM.


Market size and purchasing power					
Inpatient (hospital) sector			Outpatient (community pharmacy) sector		
Public procurement			Public procurement		
Originators	Generics	Biosimilars	Originators	Generics	Biosimilars

SCOPE



- » **Public sector** including not-for-profit
- » **Outpatient and inpatient** sectors
- » **Medicines** (including vaccines)
- » Literature and data from **2000 until 2022**

The study will utilise a **mix of methods** (literature review, data analysis, and stakeholder involvement) to create two key outputs: **a final report and an online assessment tool for PPM** (including mapping and ranking of policies as well as a cross-country comparison of PPM Key Performance Indicators).



A set of **intermediary outputs** will be produced:

- » Stakeholder mapping
- » Compilation of PPM practices
- » Barriers analysis
- » Best practices toolbox
- » Evaluation of efficiency gains
- » Analysis of hospital procurement

Country fiches /
Stakeholder interviews

Which countries apply which type of PPM policies?
Which countries use joint procurement?
Which countries apply which type of supporting policies for PPM?



Data analysis /
Savings analysis

How do countries perform in PPM?



Stakeholder survey /
Stakeholder workshops

Which policies contribute most to affordability, availability, environment, security of supply and competition?

